Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSingh, Dave
dc.contributor.authorHan, MeiLan
dc.contributor.authorBhatt, Surya
dc.contributor.authorCompton, Chris
dc.contributor.authorKolterer, Stefanie
dc.contributor.authorMiravitlles, Marc
dc.date.accessioned2025-04-08T05:56:20Z
dc.date.available2025-04-08T05:56:20Z
dc.date.issued2025-03
dc.identifier.citationSingh D, Han MK, Bhatt SP, Miravitlles M, Compton C, Kolterer S, et al. Is Disease Stability an Attainable Chronic Obstructive Pulmonary Disease Treatment Goal? Am J Respir Crit Care Med. 2025 Mar;211(3):452–63.
dc.identifier.issn1535-4970
dc.identifier.urihttp://hdl.handle.net/11351/12903
dc.descriptionChronic obstructive pulmonary disease; Disease management; Treatment outcome
dc.description.abstractChronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by progressive airflow obstruction. Despite advancements in diagnosis and treatment, the disease burden remains high; although clinical trials have shown improvements in outcomes such as exacerbations, quality of life, and lung function, improvement may not be attainable for many patients. For patients who do experience improvement, it is challenging to set management goals given the progressive nature of COPD. We therefore propose disease stability as an appropriate and attainable treatment goal. Other disease areas have developed definitions of no disease activity or remission, which provide relevant information for defining and achieving stability for patients with COPD. Disease stability builds on related concepts already defined in COPD, such as clinical control and clinically important deterioration. Current components that could form part of a disease stability definition include exacerbations, health status (including quality of life and symptoms), and lung function. Considerations should be given to intervals over which stability is defined and assessed, appropriate thresholds, and defining a composite. Ensuring a holistic approach, objective measurements, and harmonious, clear communication between patients and physicians can further support establishing disease stability. Here we propose a preliminary definition of disease stability, informed by existing research in COPD. Further research will be needed to validate the framework for use in clinical and research settings. Exploring disease stability as a goal, however, is an opportunity to develop and validate an attainable treatment target to advance the standard of care for patients with COPD.
dc.language.isoeng
dc.publisherAmerican Thoracic Society
dc.relation.ispartofseriesAmerican Journal of Respiratory and Critical Care Medicine;211(3)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPulmons - Malalties obstructives - Tractament
dc.subjectPacients - Satisfacció
dc.subject.meshPulmonary Disease, Chronic Obstructive
dc.subject.mesh/therapy
dc.subject.meshQuality of Life
dc.titleIs Disease Stability an Attainable Chronic Obstructive Pulmonary Disease Treatment Goal?
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1164/rccm.202406-1254CI
dc.subject.decsenfermedad pulmonar obstructiva crónica
dc.subject.decs/terapia
dc.subject.decscalidad de vida
dc.relation.publishversionhttps://doi.org/10.1164/rccm.202406-1254CI
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Singh D] Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust, Manchester, United Kingdom. [Han MK] University of Michigan, Ann Arbor, Michigan. [Bhatt SP] Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama. [Miravitlles M] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER de Enfermedades Respiratorias (CIBERS), Barcelona, Spain. [Compton C] Global Medical Affairs, General Medicines, London, United Kingdom. [Kolterer S] Specialty Medicines, GSK, London, United Kingdom
dc.identifier.pmid39680953
dc.identifier.wos001440726000032
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record